Stem-Cell Cosmeceutical Firm NuGene Eyes Skin-Care Drug Approvals
This article was originally published in The Rose Sheet
Executive Summary
Acne treatments and burn-relief products based on human stem-cell media may be forthcoming from NuGene International, as newly created subsidiary NuGene BioPharma looks to parlay the firm’s existing technology into skin-care pharmaceuticals subject to FDA approval.
You may also be interested in...
NuGene Growing Its Stem-Cell Cosmeceuticals Biz; Regulatory Risks Noted
NuGene's sales have soared with expanded distribution, but increased regulation continues to be a risk to its human stem-cell-based cosmeceuticals business, the firm notes. Skin and hair-care line extensions will launch later this year, and the company is considering developing an in-house sales force.
FDA Warning To L’Oreal Creates Uncertainty For Anti-Redness, Dark Spot Treatments
In a Feb. 12 warning letter, just the descriptors for two L’Oreal/La Roche-Posay products – a “Localized Redness Intensive Serum” and “Concentrated Dark Spot Correcting Serum” – are cited by FDA as evidence that the products are intended for use as drugs. The warning raises questions about the viability of those categories for cosmetics firms intent on staying off FDA’s radar.
‘Revolution’ Quelled? FDA Warns Firm For ReLuma Stem-Cell Claims
Claims promoting Cell Vitals’ ReLuma skin-care line render the products unapproved drugs, FDA asserts in a Nov. 24 warning letter. Marketed as “A Revolution in Stem Cell Skin Care,” the firm’s products feature cytokines and growth factors harvested from adult stem cells that send “grow and divide” signals to aging skin cells, the company says.